Skip to main content
Equibles
CTMX logo

CTMX · CytomX Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track CTMX — free

Use CTMX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTMX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.72 -0.03 (-1.09%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$598.13M
Shares
217.90M
Volume · Sep 30 3.22M Avg daily vol (3M) 3.54M

CytomX Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for CytomX Therapeutics, Inc. (CTMX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼36.6% $11.15M −$29.06M '22 Q3 22-11-08 ▲80.8% $20.12M −$8.78M '22 Q4 23-03-27 ▲159.9% $23.50M −$3.31M '23 Q1 23-05-09 ▲92.4% $24.72M −$1.09M '23 Q2 23-08-08 ▲136.7% $26.38M $2.99M '23 Q3 23-11-07 ▲32.2% $26.61M $837,000 '23 Q4 24-03-11 ▲76.4% $41.46M $13.79M '24 Q1 24-05-08 ▲1.6% $25.11M −$6.53M '24 Q2 24-08-08 ▲26.7% $33.43M $5.74M '24 Q3 24-11-07 ▲43.2% $38.09M $18.88M '24 Q4 25-03-06 ▲22.8% $50.92M $23.52M '25 Q1 25-05-12 ▼25.7% $18.66M −$154,000 '25 Q2 25-08-07 ▼82.2% $5.96M −$14.23M '25 Q3 25-11-06 ▼98.3% $663,000 −$26.51M '25 Q4 26-03-16 ▼79.9% $10.26M −$18.25M '26 Q1 26-05-07 LATEST ▼92.4% $1.42M −$20.67M '26 Q2 26-08-06
Conference
Investor event
2026-09-14
CytomX Therapeutics, Inc. (CTMX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
CytomX Therapeutics, Inc. (CTMX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
Confident tone Varsetta M monotherapy in late-line CRC Pan-tumor / GI expansion cohorts Registrational study planning and timelines
Revenue
$1.42M
▼ 92.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Annual General Meeting
Investor event
2026-06-17
CytomX Therapeutics, Inc. (CTMX) June 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-10
CytomX Therapeutics, Inc. (CTMX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
CytomX Therapeutics, Inc. (CTMX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
Confident tone Varsetta M (VarsettaM) in colorectal cancer Dose optimization and registrational path EPCAM targeting and ProBody platform
Revenue
$10.26M
▼ 79.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript
Confident tone Varsetta Phase 1 dose expansion efficacy in CRC Dose optimization cohorts (8.6 / 10 mg/kg, AIBW dosing) EPCAM ProBody platform and Mazatecan payload
Revenue
$663,000*
▼ 98.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript
Confident tone CX-2051 Phase I data and progress in colorectal cancer PROBODY platform and EpCAM targeting CX-801 masked interferon alpha-2b in melanoma
Revenue
$5.96M
▼ 82.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript
Confident tone CX2051 in colorectal cancer CX801 / Keytruda combination in melanoma Safety and tolerability, especially diarrhea
Revenue
$18.66M
▼ 25.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
CytomX Therapeutics, Inc. (CTMX) Q1 2025 Earnings Call
Revenue
$50.92M
▲ 22.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
Positive tone CX-2051 lead EPCAM ADC in colorectal cancer CX-801 masked interferon alpha program Unmet need and bar for activity in late-line CRC
Revenue
$38.09M*
▲ 43.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call
Revenue
$33.43M
▲ 26.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
CytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call Transcript
Confident tone CX-904 EGFR-CD3 PROBODY T-cell Engager CX-2051 EpCAM PROBODY ADC Amgen partnership and Phase 1b strategy
Revenue
$25.11M
▲ 1.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript
Confident tone CX-904 Phase Ia dose escalation data Safety profile and therapeutic window Dose optimization and step dosing strategy
Revenue
$41.46M
▲ 76.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
Positive tone CX-904 EGFRxCD3 Probody T-cell engager Upcoming pipeline milestones / catalysts CX-2051 EpCAM Probody ADC
Revenue
$26.61M*
▲ 32.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
CytomX Therapeutics, Inc. (CTMX) Q3 2023 Earnings Call Transcript
Revenue
$26.38M
▲ 136.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript
Revenue
$24.72M
▲ 92.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript
Revenue
$23.50M
▲ 159.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript
Revenue
$20.12M*
▲ 80.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Call Transcript
Revenue
$11.15M
▼ 36.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
CytomX Therapeutics, Inc. (CTMX) Q2 2022 Earnings Call Transcript
Revenue
$12.85M
▼ 21.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
CytomX Therapeutics, Inc. (CTMX) Q1 2022 Earnings Call Transcript
Revenue
$9.04M
▼ 43.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
CytomX Therapeutics, Inc. (CTMX) Q4 2021 Earnings Call Transcript
Revenue
$11.13M
▲ 57.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
CytomX Therapeutics, Inc. (CTMX) Q3 2021 Earnings Call Transcript
Revenue
$17.59M
▼ 1.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
CytomX Therapeutics, Inc. (CTMX) Q2 2021 Earnings Call Transcript
Revenue
$16.29M
▼ 1.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript
Revenue
$15.97M
▼ 67.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-19
CytomX Therapeutics, Inc. (CTMX) Q4 2020 Earnings Call Transcript
Revenue
$7.08M
▼ 14.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Call Transcript
Revenue
$17.79M
▲ 66.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
CytomX Therapeutics, Inc. (CTMX) Q2 2020 Earnings Call Transcript
Revenue
$16.61M
▲ 84.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
CytomX Therapeutics, Inc. (CTMX) Q1 2020 Earnings Call Transcript
Revenue
$49.59M
▲ 68.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
CytomX Therapeutics, Inc. (CTMX) Q4 2019 Earnings Call
Revenue
$8.28M
▼ 27.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 earnings calls
Key facts CIK 1501989 CUSIP 23284F105 13F (30d) 3 filings 3 filers Visit website Investor relations